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Abstract. Parkinson’s disease (PD) is the second most common neurodegenerative disease worldwide, characterized by
symptoms of bradykinesia, rigidity, postural instability, and tremor. Recently, there has been a growing focus on the relation-
ship between the gut and the development of PD. Emerging to the forefront, an interesting concept has developed suggesting
that the initial pathophysiological changes occur in the gastrointestinal tract before changes are seen within the brain. This
review is aimed at highlighting the relationship between PD and the gastrointestinal tract, along with the supporting evidence
for this. Firstly, we will focus on the gastrointestinal conditions and symptoms which commonly affects patients, includ-
ing both upper and lower gastrointestinal issues. Secondly, the impact of nutrition and diet on neurological health and PD
physiology, with particular emphasis on commonly consumed items including macronutrients and micronutrients. Finally,
variability of the gut microbiome will also be discussed and its link with both the symptoms and signs of PD. The evidence
presented in this review highly suggests that the initial pathogenesis in the gut may proceed the development of prodromal
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BACKGROUND23
Parkinson’s disease (PD) is characterized by dege-24
neration of the dopaminergic neurons of the sub-25
stantia nigra and spread of alpha-synuclein enriched26
Lewy bodies (LB) to other cortical and subcorti-27
cal brain areas, particularly the basal ganglia [1,28
2]. The development of LB arises from an initial29
template formed from pathological alpha-synuclein,30
which instigates seeding of nearby alpha-synuclein31
proteins. This triggers a shift from a benign -helical32
structure to a toxic, insoluble -pleated sheet struc-33
ture protein, which aggregates to form LB [3]. These
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seeds may then disseminate throughout nearby and 34
distal neurons, leading to the development and sites 35
of Lewy pathology (LP) [4]. 36
The nigrostriatal pathway plays an important role 37
in the pathophysiology of PD. The levels of dopamine 38
decrease due to the breakdown of the substantia nigra, 39
in particular, within an area called the pars compacta 40
[2]. The dopaminergic changes in PD lead to the 41
characteristic motor symptoms of PD such as muscle 42
rigidity, bradykinesia, tremor, and postural instability 43
[5]. 44
However, other symptoms, such as anosmia and 45
autonomic dysfunction are also highly common in 46
PD [6]. Of particular importance, gut symptoms have 47
received increased attention with new evidence sug- 48
gesting that PD pathophysiology may start in the gut. 49
This highlights an underexplored area of research and 50
will therefore be a focus of this review. 51
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The gastrointestinal microbiota could play an im-52
portant role in the development of PD as a link53
between the intestinal microbiota, neurodevelop-54
ment and neurological diseases are increasingly55
recognized. Neurological function is influenced by56
neuropeptides, neuronal hormones and many other57
metabolites produced within the gut, whilst the gut58
itself is heavily influenced by the central nervous59
system (CNS) [7]. The gut microbiome, made up60
of bacteria, fungi and archaea form a diverse com-61
munity that is highly variable and unique to each62
individual and encompasses a number of crucial func-63
tions, including maintaining metabolic homeostasis,64
vitamin biosynthesis, and drug modification [8].65
Gut dysbiosis, defined broadly as an alteration of66
the gut microbiome, has been associated with a67
number of inflammatory-driven diseases including68
inflammatory bowel disease (IBD), Alzheimer’s dis-69
ease (AD), and obesity [9]. Furthermore, dysbiosis70
is associated with the development of low-grade71
inflammation, increased oxidative stress, cellular72
degeneration, and disturbance of the blood-brain bar-73
rier [10]. Particular focus has aimed at investigating74
the microbiome in PD, with increasing evidence75
demonstrating differences in the gut microbiota com-76
position between PD patients and healthy controls.77
The intestinal microbiota in PD may also be involved78
in the modulation of a-synuclein aggregation and79
may further play a role in short chain fatty acid80
metabolism, a-synuclein pathology and microglial81
activation [8, 11, 12] Finally, levels of certain bac-82
terial species may influence PD symptomology [13].83
This review will cover the theory and evidence84
behind the reasons why PD may start within the gut,85
the influence of nutrition on the risk of PD and how86
variances in gut microbiota composition may con-87
tribute to the PD origins and associated symptoms.88
Our evidence for this review is sourced from key89
papers published and cited in this field, including90
case-based discussions to meta-analyses.91
BRAAK AND THE GUT THEORY92
The onset of sporadic PD is unknown, but the93
Braak hypothesis offers to explain a mechanism for94
this. Braak et al. proposed the dual-hit theory which95
suggests that sporadic PD starts in two places—the96
neurons of the olfactory system and the gastrointesti-97
nal tract (GIT) [14]. This review will only focus on98
the GIT aspect of Braak’s theory and will only briefly99
touch upon the involvement of the olfactory network.100
Braak hypothesized that a foreign pathogen, either 101
bacterial or viral, triggers a response which leads to 102
LP that affects the olfactory and GIT system [15]. 103
Subsequently, neurons allow the retrograde trans- 104
mission of alpha-synuclein enriched LB to the CNS 105
from the olfactory and the vagus nerve, respectively. 106
The transmission of alpha-synuclein pathology is 107
believed to spread across the nervous system through 108
a ‘prion-like’ fashion [16]. 109
A fundamental aspect of Braak’s theory is the 110
movement of alpha-synuclein from the enteric ner- 111
vous system (ENS) to the CNS via the vagus nerve 112
and dorsal motor nucleus of vagus within the medulla 113
oblongata [17]. The ENS is a network of neurons 114
within the gut wall which works separately from 115
the CNS [18]. The ENS consists of two plexuses, 116
myenteric and submucosal, and has a number of dif- 117
ferent roles including regulating motility, mucosal 118
blood flow and water transport [19]. The vagal nerve 119
plays an important part in functions of the body, e.g., 120
stimulating salivation, gut peristalsis, and bladder 121
contraction [20]. 122
Composed of six stages, disease progression is 123
determined by the Braak staging system. Each stage 124
represents a site of LP, starting from the ENS and 125
ascending through the brain. Stages 1 and 2 demon- 126
strate hindbrain pathology, whilst stages 3 and 4 127
involve the midbrain, where motor symptoms become 128
recognizable. Cognitive symptoms are apparent in 129
stages 5 and 6 as the full neocortex is affected [21]. 130
Braak’s theory dovetails with clinical evidence 131
of gastrointestinal symptoms, including dysphagia, 132
constipation, early satiety, bloating, and non-specific 133
abdominal pain. The presence of LP within GIT neu- 134
rons or the ENS has been reported [22–32] and LP 135
can be seen within the ENS up to 10–20 years prior 136
to the diagnosis of PD, suggesting gastrointestinal 137
dysfunction may precede the first onset of motor 138
symptoms [33]. Two independent histological stud- 139
ies have reported an abundance of alpha-synuclein 140
within the vermiform appendix and have suggested 141
that an appendicectomy, may both lower the risk of 142
developing PD and delay the age of onset [34]. A 143
large, nested control study conducted by Liu et al 144
also concluded that an appendectomy was associated 145
with a lower risk of PD [35], but interestingly, a 2021 146
meta-analysis demonstrated no significant difference 147
in emergence of PD between patients with and those 148
without an appendectomy history [36]. Moreover, LP 149
findings have also been replicated in animal mod- 150
els, with aggregations of alpha-synuclein found in 151
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Retrospective autopsy-based studies have shown153
LP in the peripheral vagal nerves [39] and this is sig-154
nificant as swallowing and excessive salivation diffi-155
culties are common in PD patients [40]. Interestingly,156
truncal vagotomy has been suggested as a protec-157
tive factor in reducing the long-term risk of PD [41].158
Although, such a radical procedure and its implica-159
tions need to be clearly further investigated [42].160
Despite the evidence suggesting that PD may start161
within the gut, limitations exist to this concept. For162
the prion hypothesis to work in the Braak staging163
criteria, Lewy pathology must be seen in the lower164
brainstem prior to the appearance of Lewy pathology165
in higher structures, e.g., stage 1 involves the dor-166
sal motor nucleus of vagus in the medulla oblongata167
as the first site of spread within the brain. However,168
patients have been found to have pathology in higher169
structures of the brain, including severe disease in170
the substantia nigra (stage 3) without involvement of171
the lower brainstem [43]. Therefore, perhaps alter-172
native routes of LP spread may be present in the173
development of PD pathology. Furthermore, alpha-174
synuclein is also a major histopathological hallmark175
of a number of different diseases such as AD, demen-176
tia with Lewy bodies, and multiple system atrophy,177
but these conditions do not show the same distribu-178
tion of pathology according to the prion hypothesis179
and Braak staging system [4, 44]. The question also180
remains whether the gut microbiota has an impact on181
the genesis of alpha-synuclein within the gut.182
Another key aspect is the movement of alpha-183
synuclein from the ENS to CNS. This mechanism has184
been countered by a study which suggests the trans-185
mission of pathology actually moves from the brain186
to the GIT founded on results displaying higher den-187
sity levels of phosphorylated alpha-synuclein in the188
spinal cord and peripheral nerves compared with the189
gut [45]. Moreover, not all PD patients have shown LP190
within the ENS [46]. Over the course of the disease191
progression, younger patients had pathology associ-192
ated with the Braak staging model over the course193
of their disease compared with elderly patients with194
a shorter disease whose symptoms did not orrelate195
[47]. Consequently, this could mean the staging sys-196
tem may be more inclined to certain phe otypes.197
Question marks also exist as to whether Lewy198
pathology is beneficial in neurodegenerative disease.199
Lewy bodies have been theorised to enclose insol-200
uble, misfolded alpha-synuclein and help facilitate201
aggresome-like degradation [48, 49]. This opposes202
the current views that Lewy pathology is a sign of203
neurodegeneration.204
Finally, while the degeneration of the nigrostriatal 205
dopamine pathway is the key characterization of PD, 206
other non-dopaminergic systems also contribute to 207
the pathophysiology. Affected neurotransmitters in 208
PD also include noradrenaline, serotonin, GABA, and 209
acetylcholine [50]. Degeneration of these neurons can 210
lead to abnormalities attributing to both motor and 211
non-motor symptoms. Braak’s theory has little ref- 212
erence to this and their involvement in PD may be 213
greater than first imagined [51]. 214
GIT SYMPTOMS 215
Aside from motor irregularities, non-motor symp- 216
toms involving the GIT are common in PD. These 217
include abnormal salivation, dysphagia, constipation, 218
abdominal bloating, early satiety, and fecal inconti- 219
nence [52]. Here we will take a closer look at the 220
reported symptoms and its link with PD. 221
Constipation 222
Constipation occurs due to delayed intestinal tran- 223
sit time and decreased GI motility, with effects 224
displayed in the small and large bowels [52, 53]. Indi- 225
viduals with chronic constipation have a 3–11-fold 226
increased risk of developing PD [54], and data from 227
both prospective and retrospective studies suggests 228
constipation becomes evident between an average of 229
15.6–24.0 years before diagnosis [55]. Interestingly, 230
middle-aged men with infrequent bowel movements 231
(< 1 bowel movement/day), had a 4 times increased 232
risk of PD diagnosis over the next 20–25-year 233
period compared with the same population with nor- 234
mal bowel movements [56]. Intestinal complications 235
arising from constipation such as sigmoid volvu- 236
lus, bowel perforation, and asymptomatic megacolon 237
may also occur [57]. 238
Defactory difficulties 239
Defecation difficulties are common in patients with 240
PD, may appear early in the disease process [58]. 241
Incoordination of the muscles of defecation such 242
as puborectalis, abdominal muscles, and diaphragm 243
may result in ineffective elimination [59]. A vital part 244
of the defecation process involves both the internal 245
and external anal sphincter muscles, with impaired 246
relaxation of these sphincters confirmed through 247
defecography and anorectal manometry studies [60, 248
61]. Consequently, as a result of defecation diffi- 249
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incontinence arises, and this can be hugely distressing251
to the patient [62].252
Inflammatory bowel disease253
Nationwide population-based studies have found a254
significantly increased risk of PD in patients suffering255
from IBD [63, 64]. IBD has a genetic susceptibil-256
ity with LRRK2, the same gene involved in sporadic257
PD [65]. It is known that the risk of ulcerative258
colitis decreases with smoking [66] and a recent259
meta-analysis has also shown that long-term smoking260
reduces the risk of PD [67]. Smoking is hypothesized261
to affect the gut microbiota and reduce the production262
of proinflammatory cytokines, thus lessening intesti-263
nal inflammation [68].264
Early satiety and bloating265
Early satiety and bloating are due to impaired gas-266
tric emptying with magnetic resonance imaging and267
electrogastrography showing gastric motility abnor-268
malities [69, 70]. Loss of neuronal function within the269
myenteric plexus and LB inclusions embodied within270
the vagus nerve slowing down intestinal peristalsis271
may cause these abnormalities [71, 72]. Gastropare-272
sis could have implications involving absorption of273
L-Dopa and thus influence the degree of motor symp-274
toms [73], whilst small bowel dysmotility may cause275
abdominal bloating and predispose to small intestinal276
bowel overgrowth (SIBO) [74].277
Dysphagia278
Dysphagia develops during the disease progres-279
sion in over 80% of patients [75]. In one-third of280
patients, the issue of swallowing arises from the281
motor symptoms of bradykinesia and tongue motor282
control [76]. Furthermore, issues with swallowing283
reflex and esophageal sphincter contractions have284
been observed [77]. LB have been detected in the285
esophageal myenteric plexus [78] with high resolu-286
tion esophageal manometry studies, barium swallow287
studies and scintigraphy studies showing abnormali-288
ties with the esophageal body and lower esophageal289
sphincter [79–81]. LP has also been discovered in290
the glossopharyngeal nerve and internal superior291
laryngeal nerve in patients with dysphagia [82]. The292
complications of dysphagia are serious, including293
malnutrition, dehydration, and aspiration pneumonia294
[83].
Hypersalivation 295
Hypersalivation and sialorrhea occurs in the later 296
stages of the disease [84]. It is thought to occur 297
in patients due to decreased swallowing frequency 298
rather than increased saliva production [85] whilst 299
other motor features, e.g., hypomimia and stooped 300
posture, may exacerbate drooling [86]. Additionally, 301
sialorrhea has been linked with an increased risk of 302
respiratory infection in patients with daily drooling 303
[87]. 304
DIET AND NUTRITION 305
Environmental factors are thought to contribute 306
to the pathogenesis and development of PD. Recent 307
research suggests that certain compounds and nutri- 308
ents may trigger the disease process whilst others may 309
in fact be neuroprotective [88]. The composition of 310
gut microbiota is also heavily influenced by diet with 311
research indicating the effect of diet on neurologi- 312
cal health is based on the gut microbiota population 313
rather than diet-induced neuro-inflammation [89]. 314
Microbiota dysbiosis has been linked to the type and 315
amount of consumption including dietary macronu- 316
trients, vegetables and dietary patterns including the 317
Mediterranean diet (MD). This aspect of the review 318
focuses on certain dietary compounds which my play 319
a role in PD physiology. 320
Caffeine 321
Caffeine has several health benefits including a 322
positive influence on cardiovascular health [90]. An 323
inverse relationship between caffeine consumption 324
and the risk of developing PD has been reported. 325
A variety of epidemiological studies have implied 326
coffee consumption as a causal factor [91–93]. 327
Experimental models have suggested adenosine A2A 328
receptors, located with D2 dopaminergic neurons 329
within the striatum, are involved in the mode of 330
action [94]. Caffeine may antagonize the A2A recep- 331
tors and accordingly stimulate the D2 receptors, 332
leading to increased motor activity and motor symp- 333
tom improvement [95]. The cytoprotective effects of 334
caffeine have been displayed through activation of 335
cell signaling pathways, particularly P13K/Akt; an 336
important pathway in downregulating neuroinflam- 337
mation [96]. Moreover, further animal studies have 338
shown caffeine increased the effect of L-dopa and 339
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Tea340
Tea has been implicated as a neuroprotective agent341
for PD [98], although some studies have contested342
this [99]. A 2012 meta-analysis confirmed tea drink-343
ing was protective but with no real dose-response344
relationship [100]; however, a 2014 meta-analysis345
did find a linear-dose relationship [101]. A 2019346
meta-analysis confirmed tea consumption was asso-347
ciated with a reduced risk of PD, and in particular,348
people who drink more than one cup of non-black349
tea daily may have a reduced risk [102]. A range350
of natural products within tea such as polyphenols,351
methylxanthine, and caffeine have been linked to a352
number of beneficial health effects [103]. Epigallo-353
catechin gallate (EGCG), a polyphenol, may promote354
neuroprotection through inhibiting the production of355
free radicals and pro-inflammatory markers within356
the brain [104]. Theanine increases dopamine lev-357
els in the brain [105] and flavonoids may help to358
facilitate increased brain blood flow through their359
anti-inflammatory effects on the circulatory system360
[106].361
Dairy362
Dairy products, e.g., milk have been associated363
with a higher incidence of PD through a number of364
worldwide epidemiological studies [107, 108] and365
this association with milk is stronger than other prod-366
ucts such as cheese and yogurts. Interestingly, a367
dose-response meta-analysis of prospective cohort368
studies determined a 17% increased PD risk for every369
200 g/day increment in milk intake [109]. Moreover,370
it is also thought high consumption of dairy products371
may lead to low serum uric acid levels in individuals372
through the influence of casein on uric acid con-373
centrations [110]. High serum uric acid levels may374
reduce the risk of PD and the duration of the disease375
[111–113]. Interestingly, this protective effect of uric376
acid has only been seen in men [88, 114].377
Fruit and vegetables378
Encompassing a number of antioxidants, a diet379
high in fruit and vegetable consumption has been380
found to lower the risk of PD [115]. Recently, the381
MD has been increasingly explored to determine382
its effects on neurological health [116]. The MD is383
characterized by high amounts of olive oil, vegeta-384
bles, fruits, fish and lower consumption of meats385
and animal fats. A meta-analysis demonstrated good386
adherence to the MD lead to significant improvement 387
in health status and reduced incidence of PD [117]. 388
Nutritional modulation of ageing pathways involving 389
brain atrophy and neuroinflammation induced by the 390
MD may explain the lower risk in PD. 391
Vitamins 392
Vitamin intake could be useful in the prevention 393
of PD. A meta-analysis has detected lower levels 394
of Vitamin B12 in PD patients compared with con- 395
trols whilst supplementation of Vitamin B6 could be 396
associated with a decreased risk of PD [118, 119]. 397
Vitamin B6, B9, and B12 are involved in homocys- 398
teine metabolism, with high levels of homocysteine 399
known to cause neurotoxicity [120]. It is still unclear 400
in the context of PD, whether high levels of homo- 401
cysteine are due to medications such as L-dopa or are 402
involved at first-hand [121]. Vitamin C, abundant in 403
the CNS, is thought to be neuroprotective but the asso- 404
ciation is controversial [122]. Intriguingly, Vitamin 405
D indirectly influences the breakdown of dopamin- 406
ergic neurons within the substantia nigra through 407
regulation of calcium [123]. Vitamin D deficiency 408
has been detected in patients, with supplementation 409
improving PD motor symptoms [124, 125]. Higher 410
dietary consumption of vitamin E, another neuropro- 411
tective agent, a was also found to reduce PD risk 412
[122, 126]. 413
Fats 414
The relationship with the consumption of dietary 415
fats with PD risk has been widely reported, albeit 416
with inconsistent findings. A 2019 meta-analysis 417
expressed an association between high intake of ani- 418
mal fat and the risk of PD, and this depends on the 419
subtype of fat, for instance, arachidonic acid and 420
cholesterol may increase PD risk [127]. Interestingly, 421
N-3 polyunsaturated fatty acids (PUFAs) may reduce 422
PD risk [128]. Located in neuronal membranes, an 423
abundance of PUFAs within the brain is thought to 424
provide a neuroprotective effect [129], whilst it has 425
been demonstrated that PUFA deficiency may lead to 426
poor brain function [130]. The evidence that PUFA 427
may decrease PD risk is further strengthened as - 428
linolenic acid, a fatty acid precursor, demonstrates an 429
inverse association with PD risk [131]. A ketogenic 430
diet trialed in animal and clinical trials was success- 431
ful in improving parkinsonism [132] with a Unified 432
Parkinson’s Disease Rating Scale (UPDRS) impro- 433
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contained low protein which could increase the435
bioavailability of L-dopa [134].436
Carbohydrates437
Similar to dietary fats, studies evaluating the438
impact of carbohydrates has also been reported, with439
conflicting reports [135]. Carbohydrates may influ-440
ence dopamine production in the brain by initiating441
easy passage of its precursor, tyrosine, through the442
blood-brain barrier [136]. Additionally, an insulin443
surge through the consumption of high glycemic444
index carbohydrates may also increase dopamine pro-445
duction [137]. A pilot randomized controlled trial446
investigating the efficacy of a low-fat, high carbo-447
hydrate diet against a ketogenic diet demonstrated448
a significant improvement in both motor and non-449
motor symptoms, albeit a greater improvement in the450
ketogenic diet [138]. Nonetheless, the link between451
carbohydrate consumption and PD risk may not be452
clinically significant. For instance, a high carbohy-453
drate diet is known to cause an increased risk of454
type 2 diabetes mellitus (T2DM] [139]. Theoretically,455
these patients with T2DM should have a lower risk of456
PD due to the effect of carbohydrates on dopamine457
production. However, the link between T2DM and458
PD has been extensively investigated, with a system-459
atic review demonstrating inconsistent reports [140].460
Therefore, clinically a balanced healthy diet should461
always be advised in all patients as primary and sec-462
ondary prevention to reduce risk of other diseases,463
e.g., cardiovascular, metabolic. On a side note, the464
effect of certain anti-diabetic medications in patients465
with both PD and T2DM may have an important466
role in influencing PD symptomology. Excitingly,467
incretin mimetics such as exenatide may be neuropro-468
tective and in a double-blinded randomized control469
trial demonstrated a statistically significant improve-470
ment in the UPDRS score [141]. Possible reasons for471
the neuroprotective effects of incretin mimetics may472
include increase tyrosine levels in neurons and inhi-473
bition of microglial activation [142]. Research into474
these medications may well lead to future therapeutic475
treatments for patients with or without diabetes.476
THE GUT MICROBIOTA477
Growing evidence suggests that a relationship478
exists between PD and the gastrointestinal micro-479
biota. The GIT consists of an incredibly diverse and480
complex population of microorganisms, which co-481
exists symbiotically with the host and plays a crucial482
rule in enhancing overall host health [143]. In early 483
life the microbiota changes rapidly and is fundamen- 484
tal in the development and promotion of the immune 485
system [144]. By the age of 3 years the gut micro- 486
biota stabilizes but remains susceptible to a large 487
range of environment and host factors. A change 488
in the microbial composition towards a maladaptive 489
and pathogenic profile [145], also called dysbiosis, 490
has been associated with a wide range of conditions 491
including type 1 diabetes mellitus, IBD, and a range 492
of neurodegenerative conditions such as AD, amy- 493
otrophic lateral sclerosis, and PD [146, 147]. 494
A number of studies reported that patients with 495
PD were found to have significantly reduced lev- 496
els of bacterial diversity when compared against a 497
healthy population [148–154]. Until 2019, 16 human 498
case control studies have investigated the role of 499
gut microbiota in PD, with over 100 different bac- 500
terial taxonomic levels reported. Between healthy 501
controls and PD patients, all 16 case-control stud- 502
ies reported statistically significant differences [13]. 503
A recent 2021 meta-analysis by Romano et al con- 504
firmed consistent differences between the average 505
gut-microbiota levels between health controls and 506
patients with PD [12]. 507
The bacterial taxa highlighted in this review 508
were chosen as previous studies including the meta- 509
analysis by Romana et al, have shown that there 510
is distinct variation in the gut microbiota profiles 511
between healthy controls and PD patients. Different 512
relative abundances of the selected taxa have been 513
shown by other studies to be associated with PD 514
physiology and symptomology. 515
The composition of gut bacteria has been shown to 516
be different in patients with both early and advanced 517
PD [154]. Intestinal microbial overgrowth is due to 518
an increase in coliform bacteria and has been discov- 519
ered to be a common occurrence in PD patients [155, 520
156]. Concentrations of urinary indican, a marker for 521
microbial dysbiosis, demonstrated a nearly two-fold 522
increase [157, 158] which indicates that microbiota 523
may play a part in PD pathogenesis. 524
Ralstonia, Eubacterium, Enterobacteriaceae 525
Fecal microbiota from PD patients shows higher 526
levels of pro-inflammatory gram-negative bacteria 527
from the Ralstonia genus [159]. Higher UPDRS 528
scores in PD patients were also associated with 529
increased levels of Eubacterium eligens, Eubac- 530
terium rectale, and Eubacterium hallii, correspond- 531
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fecal analysis has shown an increase in Enterobac-533
teriaceae family bacteria which may be linked with534
worsening postural instability and gait disturbances535
[151].536
Prevotella537
In contrast, beneficial and anti-inflammatory bac-538
teria were reduced in feces, most notably with lower539
levels of prevotellaecea [160]. Prevotella, a gram-540
negative bacterium and belonging to the phylum541
Bacteriodetes, is important in the degradation of542
complex carbohydrates to produce short-chain fatty543
acids. Folate and thiamine are also by-products and544
alongside short-chain fatty acids promote a healthy545
microbial environment [161, 162]. Decreased levels546
of Prevotella are associated with reduced mucin pro-547
teins [163]. Mucin proteins are required to line the548
mucosal surfaces and maintain the epithelial barrier549
of the intestines. Low mucin leads to increased intesti-550
nal permeability, a sign associated with PD [164].551
Additionally, Prevotella levels were also decreased552
in idiopathic rapid eye movement behavior sleep dis-553
orders (IRBD) [165]. This is intriguing as the onset554
of IRBD in the majority of times precedes the diag-555
nosis of PD and in the early stages, could potentially556
act as a clinical biomarker [166]. Prevotella copri,557
a species of the genus Prevotella, was also lower in558
abundance in a number of different neurodegener-559
ative conditions, e.g., multiple system atrophy and560
multiple sclerosis. This suggests that higher levels of561
Prevotella may play a protective role and may be a562
promising future therapeutic target [149, 159, 167].563
However, as Prevotella encompasses a number of dif-564
ferent species, it may be unreliable to generalize these565
findings.566
Lactobacillus567
Lactobacillus, a gram-positive bacterium belong-568
ing to the Phylum Firmicutes, were found to also569
be affected in PD [12]. Higher levels of Lacto-570
bacillus combined with a decrease in Prevotella571
has been associated with lower concentrations and572
altered secretions of ghrelin [152]. Ghrelin, known573
as the ‘hunger hormone’, is released by the stomach574
and small intestine [168]. The relationship between575
ghrelin and PD is not fully understood, but ghrelin576
may be involved in the maintenance of the nigros-577
triatal dopamine pathway [163]. Increased levels578
of Lactobacillus may be caused by frequent con-579
stipation as Lactobacillus is association with IBS580
type constipation [169]. Its potential as a probiotic 581
treatment, particularly using the strain Lactobacillus 582
casei, which has been observed to be an effective ther- 583
apeutic in PD through improving stool consistency 584
and bowel habit [170], is currently underway. 585
Blautia and Coprococcus 586
A decrease in anti-inflammatory species rom the 587
Blautia and Coprococcus genus were also confirmed 588
in fecal microbiota studies [12]. Bacterial strains 589
belonging to these two taxa produce the short-chain 590
fatty acid butyrate which is important in stimulating 591
intestinal mucus and regulating tight junction pro- 592
teins to maintain the epithelial lining of the colon 593
[171]. As only small amounts of butyrate are found 594
in natural food e.g., milk and cheese, the majority 595
of butyrate is sourced from the gut [172]. The levels 596
of gut butyrate may influence GIT symptoms such 597
as constipation, with butyric acid found to increase 598
peristaltic efficiency by improving the contraction 599
of intestinal smooth muscle and regulating intestinal 600
neuropathways [173]. Butyric acid may also cause 601
reduced water secretion from the GIT, which could 602
also contribute to constipation [174]. Perhaps supple- 603
ments with sodium butyrate may be beneficial as this 604
has been seen to improve locomotor symptoms [175]. 605
Akkermansia 606
Species from the Akkermansia genus of the Verru- 607
comicrobia phylum were higher in numbers in PD 608
patients [12]. Representing between 1–4% of gut 609
microbiota, Akkermansia has been associated with 610
conditions like obesity and diabetes and is known 611
to help regulate mucin levels within the intestinal 612
tract [176]. The combination of the mucous layer 613
made from mucin and the gut microbiome is recog- 614
nized as the biofilm [177]. The biofilm helps protect 615
against intestinal injury and consequently intestinal 616
permeability. Intestinal permeability or ‘leaky gut’ 617
can generate both local and systematic inflammation. 618
High levels of Akkermansia may cause intestinal per- 619
meability as the species requires mucous for energy 620
thereby causing a breakdown of the biofilm [178]. 621
Helicobacter 622
Helicobacter pylori (H.pylori) infections and sub- 623
sequently gastric ulcers are less common in the 624
general population than in PD patients [179, 180]. 625
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[181], whilst several case control studies found the627
H. pylori antibody to be five times more common628
in PD [182]. A double-blinded randomized control629
trial to investigate the relationship between idio-630
pathic PD and H. pylori, was shown to worsen631
stride length and rigidity in PD in patients with H.632
pylori and eradication of the bacteria was found633
to improve symptoms—H. pylori may impede the634
absorption of levodopa which leads to worsening of635
motor impairments [183]. Follow up studies with636
H. pylori revealed an elevated immune response,637
with high levels of natural killer cells and CD4 T-638
helper cells associated with worsening PD symptoms;639
this includes increased muscle rigidity and decreased640
free-walking speed [184]. Two proposed theories641
explain the pathophysiological relationship between642
H. pylori and PD. Firstly, H. pylori causes a neu-643
rotoxic effect by increased cholesterol glucosides,644
and this subsequently degrades dopaminergic neu-645
rons within the brain [185]. Secondly, poor immune646
control leads to H. pylori crossing the blood-brain647
barrier and this initiates apoptosis of dopaminergic648
neurons [186, 187].649
Small intestinal bacterial overgrowth650
A recent meta-analysis found a strong associa-651
tion between SIBO and PD, with around 50% of652
patients diagnosed with SIBO (188). Gastroparesis653
and abnormal motility of the GIT are cited as pos-654
sible causes [189]. Disruption of the small bowel655
epithelium may lead to increased intestinal perme-656
ability, therefore making it more prone to bacteria657
and foreign pathogens [74]. Similar to H. pylori, this658
condition is linked to motor dysfunction and treat-659
ment with antibiotics improves symptoms. Finally,660
the same study also noted increased bacterial over-661
growth may predispose to the poor absorption of662
L-Dopa [189].663
However, it is important to note that these results664
must be taken with caution. Investigating the vari-665
ances in gut microbiota is a challenging area of666
research, particularly because of differences in study667
methodologies and the inherently large variability668
of gut microbiota composition between participants.669
Boertien et al. discussed the implications of com-670
paring and analyzing data between gut microbiome671
studies in PD. From variation in sample size to influ-672
ence of confounding variables, many factors need to673
be considered when interpreting the inconsistency674
of study results. It is therefore difficult to estab-675
lish whether taxonomic changes are related to PD676
pathology. Robust methodology through standard- 677
ization of research protocols and collection of 678
confounders is important to produce data homoge- 679
nization. An integrative dataset with all sequencing 680
data should be available publicly to address these 681
confounders, with further expansion of atypical 682
parkinsonism and prodromal PD data required to 683
thoroughly investigate this area [13]. 684
Heinzel et al. recently investigated the associations 685
between gut microbial composition, prodromal and 686
risk markers of PD. Markers including constipation, 687
physical activity, smoking, IRBD and subthreshold 688
parkinsonism were associated with variances in gut 689
composition, with findings suggesting the micro- 690
bial composition of the gut may be altered in the 691
prodromal phase. Although, it was noted that other 692
predictive markers of prodromal PD did not show a 693
significant link with microbial changes such as olfac- 694
tory loss, positive family history of PD, orthostatic 695
hypotension, depression, and erectile and urinary 696
dysfunction [190]. 697
CONCLUSION 698
In conclusion, increasing evidence suggests a 699
strong relationship between gut microbiota and PD. 700
The gut influence is thought to be larger than first 701
believed, with Braak’s hypothesis the most promising 702
in explaining a GIT impact in PD pathophysiol- 703
ogy. This theory has been supported through a 704
range of pathological studies investigating the role 705
of -synuclein and other neuropathological changes 706
within the disease progression. Clinical studies have 707
provided further supplementary evidence of GIT 708
symptomology, dietary impact, and changes in gut 709
microbiota levels in PD. 710
The variety of GIT symptoms and conditions 711
experienced by patients may be associated with the 712
underlying pathophysiological origins of the disease. 713
Recognition of these symptoms in the early stages 714
of the disease could be important indicators leading 715
to a prompt diagnosis and improved holistic man- 716
agement. However, it is important to note that the 717
gut/microbiota may not be entirely involved in the 718
prodromal phase of all PD patients and as such a 719
focused systemic approach should be undertaken as 720
suggested by Heinzel et al. [190]. Furthermore, at 721
present, limited studies have explored the role of gut 722
symptoms in early-disease stages. By detecting GIT 723
symptoms in the early stages, it could be possible 724
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Current evidence indicates that diet is important727
in PD development and progression. Food therapies728
could not only be imperative in lowering the risk729
of PD, but also improve symptom severity. Com-730
bined with current medication, nutritional approaches731
might also improve bioavailability and pharmacolog-732
ical effects. The majority of dietary findings in PD733
studies are based on either epidemiological or meta-734
analyses, with little information on how diet impacts735
on an individual level. More research in this area736
is needed as it may provide novel insight into the737
importance of nutrition on symptom severity and gut738
microbiota changes, which in turn could provide the739
basis for new treatments. The link between PUFA’s740
and PD should be thoroughly investigated as this741
is still unclear. Studies have suggested PUFA’s may742
have anti-inflammatory and neuroprotective proper-743
ties, with increased consumption of PUFA’s shown744
to reduce PD risk. However, other studies suggest745
PUFA’s may lead to neuronal degeneration within the746
substantia nigra through the involvement of oxidative747
radical formation. With further investigation, these748
food compounds could easily be tailored in everyday749
diet to adjust the risk of PD accordingly. Moreover,750
the MD could also be a key step in PD research. The751
clear health benefits of this diet are well known, and752
through either a prospective cohort or case-control753
study, the results may impact on our everyday diet.754
Finally, vitamins have been thought to influence the755
risk of PD although the link is still debatable. Vita-756
mins C, D, and E are theorized to be neuroprotective,757
and through investigating the role of multivitamins758
in PD, perhaps by taking a daily multivitamin tablet,759
the advantages may include reducing risk, improv-760
ing symptomology, and with widespread multisystem761
benefits.762
There are limitations to our review article which are763
needed to be taken into consideration. For the purpose764
of the current review, we deliberately chose a narra-765
tive review since the current research body on this766
topic is very limited making a systematic review less767
feasible. Instead, we wanted to raise the awareness of768
the topic and its current research findings to the wider769
research community. Throughout this paper we have770
added limitations and future directions highlighting771
the need for forthcoming systematic reviews. We have772
also used recent high-quality research where applica-773
ble, e.g., from meta-analyses and articles to ensure the774
content in our review is reliable and reduce bias.775
As summarized in this review, the role of gut micro-776
biota in PD is suggested to be significant. Variances777
gut in the microbiome profiles of PD patients are778
associated with dysbiosis which in turn is linked with 779
gastrointestinal disease and parkinsonian features. 780
Lactobacillus and Prevotellacea are the two most 781
exciting bacterial taxa which are linked with PD. In 782
particular, the role of these species within probiotics 783
and fecal transplantation may be a successful future 784
treatment in PD. A study researching these specific 785
probiotics in a prospective cohort study of PD patients 786
would be a step in discovering the viability of these 787
treatments. It would be also of interest if research 788
explored the impact of nutrition on gut microbiota, 789
particularly in members of the same household. The 790
rationale behind recruiting cohabiting couples who 791
live together involves similar dietary patterns and 792
environmental microbiota. This dyadic approach has 793
been shown to reduce the variability in background 794
diet patterns and microbiota composition. Finally, to 795
note, there has been little exploration into the differ- 796
ent stages of PD and gut microbiota. Longitudinal 797
studies in the prodromal as well as clinical phase 798
of PD considering multi-omics, environmental and 799
deeply phenotypic clinical data may advance our 800
understanding of the links between microbiota and 801
PD. 802
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